Molecular Assessment and Preclinical Studies (MAPS), is a newly formed Core established to assist Cancer Center and University researchers in conducting in vivo (animal) testing of novel anti-cancer therapeutics and monitoring clinical trials by molecular analysis. The MAPS Core grew out of the Cancer Center research retreat in 2004-during which Dr. Weber led a discussion on """"""""developing infrastructure that would assist basic scientists at UVa in translational cancer research."""""""" Since that time, the MAPS Core has emerged as a centralized Core focused at providing Cancer Center investigators access to 1) standardized, cost effective preclinical models, 2) in-house drug development expertise and 3) molecular tools for effective monitoring of targeted therapies in animal and clinical trials. Our ultimate mission is to create novel UVa therapies and monitor cancer trials in order to combat cancer and improve the care of our patients. The MAPS Core is divided into two divisions: molecular assessment and preclinical studies. Molecular assessments offer a wide array of molecular profiling assistance to investigators performing pre-clinical (animal) and clinical (human) trials. These efforts are focused at assisting investigators in: 1) developing custom protein microarrays, 2) standardizing normal mouse tissue arrays for immunoblotting with custom or commercial antibodies, 3) creating a directory of assessable human cancer cell lines and 4) providing cell culture assistance, 5) molecular analysis on human cell lines and tissue samples and 6) educating and training clients in molecular analysis. Preclinical studies will assist investigators, interested in developing new therapies, with a range of activities including: 1) mouse models (efficacy and toxicity assessment), 2) expert technical support in animal cancer model design, animal protocol writing and analysis of drug studies and 3) educating and training clients in the performing animal models and surgical techniques needed for specialized animal studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-19
Application #
7771669
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
19
Fiscal Year
2009
Total Cost
$50,021
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148

Showing the most recent 10 out of 539 publications